ReviewCurrent opinion in nephrology and hypertension2009
Angiogenesis in the kidney: a new therapeutic target?
Review in Current opinion in nephrology and hypertension, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Transcriptome meta-analysis and validation to discovery of hub genes and pathways in focal and segmental glomerulosclerosis.BMC nephrology · 2024Pooled it
- Molecular mechanisms and therapeutic advances of peritubular capillary neogenesis in acute kidney injury.Frontiers in molecular biosciences · 2025Review
- Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis.Thrombosis and haemostasis · 2023Article
- From AKI to CKD: Maladaptive Repair and the Underlying Mechanisms.International journal of molecular sciences · 2022Review
- Endostatin in Renal and Cardiovascular Diseases.Kidney diseases (Basel, Switzerland) · 2021Review
- Opioid Preconditioning Modulates Repair Responses to Prevent Renal Ischemia-Reperfusion Injury.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Tissue hypoxia, inflammation, and loss of glomerular filtration rate in human atherosclerotic renovascular disease.Kidney international · 2019Article
- Hyperactive FOXO1 results in lack of tip stalk identity and deficient microvascular regeneration during kidney injury.Biomaterials · 2017Article
- Vascular endothelium in diabetes.American journal of physiology. Renal physiology · 2017Review
- Renal Arterial Disease and Hypertension.The Medical clinics of North America · 2017Review
- Effects of long-acting erythropoietin analog darbepoetin-α on adriamycin-induced chronic nephropathy.International urology and nephrology · 2016Article
- Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.Biochimica et biophysica acta · 2015Review
- Obesity and renovascular disease.American journal of physiology. Renal physiology · 2015Review
- Gained in translation: protective paradigms for the poststenotic kidney.Hypertension (Dallas, Tex. : 1979) · 2015Review
- Blockade of the renin-angiotensin system in hypertensive patients with atherosclerotic renal artery stenosis.Current hypertension reports · 2013Review
- Proteomic profiling and pathway analysis of the response of rat renal proximal convoluted tubules to metabolic acidosis.American journal of physiology. Renal physiology · 2013Article
- Obesity-metabolic derangement preserves hemodynamics but promotes intrarenal adiposity and macrophage infiltration in swine renovascular disease.American journal of physiology. Renal physiology · 2013Article
- Percutaneous revascularization for ischemic nephropathy: the past, present, and future.Kidney international · 2013Review
- Increased susceptibility to kidney injury by transfer of genomic segment from SHR onto Dahl S genetic background.Physiological genomics · 2012Article
- Elevated plasma levels of endostatin are associated with chronic kidney disease.American journal of nephrology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThe prevalence of chronic kidney disease has been growing consistently for the past decades. Renal failure is often associated with defective angiogenesis, and recognition of the contribution of the renal microcirculation to the progression of chronic renal disease may aid in the development of therapeutic interventions. RECENT
findingsIntra-renal proliferation, remodeling, and/or rarefaction of microvessels in response to injury can all aggravate nephron damage, and experimental evidence suggests that they may constitute the early steps in the complex pathways involved in progressive renal injury. Recent studies showed the benefits of targeted interventions deemed to promote neovascularization (e.g. progenitor cells, growth factors) on the ischemic myocardium and brain and in a few models of renal disease. SUMMARY: Evidence of aberrant renal microvascular architecture in various forms of renal disease provides the impetus to attempt modulating the renal microcirculation to interfere with the disease process. Targeted interventions to preserve the renal microcirculation may not only decrease the evolving injury in renal vascular disease but also potentially constitute a coadjuvant intervention to become part of a comprehensive management plan to improve the success of parallel strategies to preserve renal function, such as revascularization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.